Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 20/20 | 0.47 |
| ▸ | DPP4 | P27487 | 19/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738064 | 0.85 | DPP4 (0.40) | DPP7DPP4DPP9DPP8KCNH2 | |
| SCHEMBL14738746 | 0.85 | DPP4 (0.40) | DPP7DPP4DPP9DPP8KCNH2 | |
| SCHEMBL4314190 | 0.77 | KDM4E (0.40) | DPP7DPP4DPP9DPP8 | |
| Trifluoroacetic Acid SCHEMBL16114304 | 0.75 | PIK3CD (0.42) | DPP7DPP4DPP9DPP8 | |
| Trifluoroacetic Acid SCHEMBL14738383 | 0.75 | DPP4 (0.44) | DPP7DPP4DPP8 | |
| SCHEMBL24640621 | 0.74 | S1PR5 (0.42) | — | |
| SCHEMBL4327148 | 0.74 | DPP4 (0.35) | DPP4DPP9DPP8 | |
| Trifluoroacetic Acid SCHEMBL14738316 | 0.74 | DPP4 (0.64) | DPP7DPP4DPP9DPP8KCNH2 | |
| Trifluoroacetic Acid SCHEMBL31124702 | 0.73 | GLA (0.40) | DPP7DPP4DPP9DPP8 | |
| Trifluoroacetic Acid SCHEMBL18205184 | 0.73 | CYP3A4 (0.41) | DPP7DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | DPP7 1316/4885DPP4 1636/4885DPP9 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.